Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spectrin beta chain, erythrocytic (SPTB) is a major cytoskeletal protein found primarily in red blood cells, where it forms heterotetramers with alpha-spectrin, interacting with other membrane proteins such as ankyrin and actin to maintain erythrocyte membrane stability and flexibility. Deficiencies or mutations in SPTB compromise membrane integrity and are clinically associated with hereditary spherocytosis, hereditary elliptocytosis, hereditary pyropoikilocytosis, and other hemolytic anemias, leading to abnormal erythrocyte morphology and increased cell fragility. The protein is not considered a therapeutic target, but its function is critical for erythrocyte health.
Not applicable (SPTB is not directly targeted by drugs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spectrin beta chain, erythrocytic (SPTB).